Pharmaceutical

Eli Lilly Leadership Changes Eli Lilly Eli Lilly announces major leadership changes, appointing Thomas J. Fuchs as its first Chief AI Officer, highlighting the company's commitment to AI-driven healthcare innovation. Additionally, Yan Qiong joins as VP of the Diabetes Business Unit, boosting growth in China's market.
Big Pharma to Shape the Future of Cell and Gene Therapy Catapult Matthew Durdy, CEO of Cell and Gene Therapy Catapult, led a panel at the 2024 MESA Conference alongside pharma leaders from Pfizer, Bayer, BMS, and Eli Lilly. They discussed Big Pharma's growing role in the cell and gene therapy sector, addressing commercialization challenges.
Victory! FDA Approves Pfizer's Hemophilia A or B Antibody Drug Marstacimab Pfizer FDA approves Pfizer’s new hemophilia drug, marstacimab (Hympavzi), for preventing bleeding episodes in patients with hemophilia A or B. The once-weekly therapy, priced at $795,600 per year, offers moderate improvements and aims to capture market share through its convenience.
ERLEADA® Outperforms Enzalutamide in Study Johnson & Johnson Johnson & Johnson’s study at the European Congress of Oncology Pharmacy reveals that ERLEADA® (apalutamide) significantly improves overall survival compared to enzalutamide in metastatic castration-sensitive prostate cancer, reducing death risk by 23% at 24 months.
FDA Approves Zenrelia for Itch Control in Dogs with Allergies FDA Zenrelia FDA Approves Zenrelia for Itch Control in Dogs with Allergies. Zenrelia (ilunocitinib tablets) is a new FDA-approved medication for managing pruritus and allergic dermatitis in dogs aged one year and older
FDA Approves Filsuvez®: Birch Triterpenes Gel for EB FDA Betulin FDA approved Amryt Pharma’s Filsuvez® (Birch Triterpenes Gel) for treating Junctional and Dystrophic Epidermolysis Bullosa in patients 6 months and older. Filsuvez® is now a recognized Orphan Drug, Rare Pediatric Disease, and Fast Track therapy, following its EMA approval in June 2022.
FDA Approves Lazertinib and Amivantamab for First-Line NSCLC Treatment FDA The FDA has approved lazertinib (Lazcluze) and amivantamab-vmjw (Rybrevant) for the first-line treatment of advanced non-small cell lung cancer (NSCLC) with specific EGFR mutations. The combination therapy showed significant improvement in progression-free survival in the MARIPOSA trial.
AbbVie Reports Strong Q2 2024 Performance, Adjusts Full-Year EPS Guidance Financial statements AbbVie AbbVie reports Q2 2024 revenue growth of 4.3% to $14.462 billion, driven by Skyrizi and Rinvoq. Despite robust sales, GAAP EPS fell by 32.5% due to IPR&D expenses. Oncology and Neuroscience portfolios also showed solid gains
Pfizer Q2 2024: 14% Growth in Non-COVID Products, Raises Full-Year Revenue Guidance Financial statements Pfizer Pfizer reports a 2% revenue increase in Q2 2024, driven by 14% growth in non-COVID products like Seagen and Vyndaqel. Full-year revenue guidance raised to $59.5-$62.5 billion, with adjusted EPS guidance increased to $2.45-$2.65.
CHMP July 2024 Meeting: 14 New Medicines Recommended EMA CHMP's July 2024 meeting recommended 14 new medicines and 11 indication expansions. Highlights include new treatments for eczema, liver disease, and cancer, plus six biosimilars and one generic.

< Pre 1...80 81 828384 85 86...87 Next >

Articles Archives

Hot Articles

Related Exhibition

All Categories

Agri & Industry Cosmetic Food History Laboratory

HOT Topics

Hot Articles